We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Non-Invasive Melanoma Test Ushers in New Era in Skin Cancer Detection

By LabMedica International staff writers
Posted on 25 Jan 2023

Skin cancer overall is the most common form of cancer with melanoma being the third most common and also the most aggressive form of skin cancer. More...

Now, an innovative test painlessly collect cells from the skin and applies precision genomics to diagnose melanoma accurately and at the earliest curable stage.

The DermTech Melanoma Test from DermTech (La Jolla, CA, USA) is a non-invasive genomic test that enables early detection of melanoma by identifying the presence of genomic markers found in melanoma – often much earlier than the current biopsy pathway. The Smart Sticker gently lifts skin cells containing genomic material from the surface of the skin while the adhesive on the sticker stores and preserves the skin cells so that it can be sent to DermTech’s Gene Lab for examination.

Using a proprietary precision genomic test, DermTech’s genomic analysis looks for melanoma at the gene level, 10,000 times closer than even a microscope. The test detects LINC00518 and PRAME using RT-PCR which makes billions of copies of these genes. An additional test can also be conducted to identify the presence of TERT gene driver mutations using a DNA sequencing technique. Positive results for LINC00518, PRAME, or TERT correlate with the presence of melanoma. If the genomic markers found in melanoma are present, this will typically result in a biopsy of the spot. If the biomarkers are not detected (meaning negative results), there could be a greater than 99% probability that the mole being tested is not melanoma.

The Smart Sticker uses a specially formulated adhesive to gently lift skin cells from the surface of the skin, but it is not strong enough to cause pain, bleeding or damage to the site. The DermTech Melanoma Test is not a replacement for a biopsy. If the genomic markers exist, then the doctor can use this information to choose the best path forward for the patient’s treatment. The DermTech Melanoma Test is rather a step before a biopsy that can see genomic markers linked to melanoma far earlier than the traditional biopsy pathway can.

Related Links:
DermTech


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.